Aurinia Pharmaceuticals Inc. Forecast, price target & analysts
Aurinia Pharmaceuticals Inc. Target price 2026 - Analyst rating & recommendation
Aurinia Pharmaceuticals Inc. Classifications & Recommendation
Aurinia Pharmaceuticals Inc. Price Target
| Target Price | $17.34 |
| Price | $16.90 |
| Potential |
2.60%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Aurinia Pharmaceuticals Inc. 2027 .
The average Aurinia Pharmaceuticals Inc. target price is $17.34.
This is
2.60%
register free of charge
$22.05
30.47%
register free of charge
$16.16
4.38%
register free of charge
|
|
| A rating was issued by 13 analysts: 10 Analysts recommend Aurinia Pharmaceuticals Inc. to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Aurinia Pharmaceuticals Inc. stock has an average upside potential 2027 of
2.60%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 283.06 | 336.87 |
| 20.38% | 19.01% | |
| EBITDA Margin | 44.52% | 60.53% |
| 176.47% | 35.97% | |
| Net Margin | 101.46% | 37.99% |
| 4,049.03% | 62.56% |
9 Analysts have issued a sales forecast Aurinia Pharmaceuticals Inc. 2026 . The average Aurinia Pharmaceuticals Inc. sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Aurinia Pharmaceuticals Inc. EBITDA forecast 2026. The average Aurinia Pharmaceuticals Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Aurinia Pharmaceuticals Inc. Analysts have issued a net profit forecast 2026. The average Aurinia Pharmaceuticals Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 2.07 | 0.96 |
| 5,075.00% | 53.62% | |
| P/E | 17.55 | |
| EV/Sales | 5.54 |
8 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast for earnings per share. The average Aurinia Pharmaceuticals Inc. EPS is
This results in the following potential growth metrics and future valuations:
Aurinia Pharmaceuticals Inc....
Current Aurinia Pharmaceuticals Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 07 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Dec 03 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Nov 07 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Aug 01 2025 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 16 2024 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 09 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 07 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Dec 03 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Nov 07 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 01 2025 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 16 2024 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 09 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
